Apparent discontinuation rates in patients prescribed lipid-lowering drugs

Medical Journal of Australia

Volumn 164, Issue 4, 1996, Pages 208-211

  Simons, Leon A ^a,b   Levis, Graham ^a   Simons, Judith ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CITY; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 0030044261     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1996.tb94138.x     Document Type: Article

References (6)

1. Law MR, Wald NJ Thompson SG By how much and how quickly does reduction in serum cholesterol concentration lower risk of isohaemic heart disease? BMJ 1994, 308 367-373
2. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 1994, 344. 1383-1389
3. Andrade SF Walker AM Gottlieb LK, et al Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995 332 1125-1131
4. SPSS version 5 [computer program] Michigan SPSS Inc 1992
5. Thurmer HL, Lund-Larsen PG. Tverdal A Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study J Hypertension 1994 12 481-490
6. Donovan JL Blake DR Patient non-compliance deviance or reasoned decision-making? Soc Sci Med 1992, 34 507-513